Amarin Corporation PLC Stock News

Soleno Therapeutics has seen a surge in stock value after positive data from Phase III trials of its Diazoxide Choline Extended-Release tablet for Prader-Willi Syndrome. The data showed improvements i

Amarin's (AMRN) third-quarter 2023 earnings and revenues beat estimates. Vascepa sales in the United States decline year over year.

Amarin Corporation plc (NASDAQ:AMRN ) Cantor Fitzgerald Annual Global Healthcare Conference September 26, 2023 9:55 AM ET CompanyParticipants Patrick Holt - President and CEO Conference Call Participa

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is sc

Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are

Amarin (AMRN) decides to initiate a restructuring plan to maximize cash flow opportunities in the United States. It also reports preliminary product revenues of around $65 million in Q2.

Amarin recently acquired a completely revamped management. There seems to be no radical shift in strategy, however. Therefore, there is no radical change in my negative opinion on the outlook.

Start Time: 17:40 January 1, 0000 6:14 PM ET Amarin Corporation plc (NASDAQ:AMRN ) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023, 17:40 PM ET Company Participants Aaron Berg - I

DUBLIN, Ireland and BRIDGEWATER, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Aaron Berg, Amarin's Interim President and Chief Executive Officer an

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President &

Sarissa Capital has taken full control of Amarin. The previous management was doing some slow but decent work, but did not get time to show results.

Two economic reports point to a possible recession later this year. Investors sold off risky biotech stocks as a result.

Shares of Amarin Corp. AMRN, -5.19% rose dropped 5.5% toward a near three-month low in premarket trading Friday, after the biopharmaceutical company focused on therapies for cardiovascular health disc